Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Debt (2020)

Historic Non-Current Debt for Foghorn Therapeutics (FHTX) over the last 1 years, with Q4 2020 value amounting to $19.7 million.

  • Foghorn Therapeutics' Non-Current Debt changed N/A to $19.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $19.7 million, marking a year-over-year change of. This contributed to the annual value of $19.7 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q4 2020, Foghorn Therapeutics' Non-Current Debt is $19.7 million.
  • In the past 5 years, Foghorn Therapeutics' Non-Current Debt ranged from a high of $19.7 million in Q4 2020 and a low of $8.8 million during Q3 2020